1-3 of 3
ixazomib
Close
Sort by
Journal Articles

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

Clinical Trials & Observations
Jorge J. Castillo, Kirsten Meid, Catherine A. Flynn, Jiaji Chen, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Guang Yang, Zachary Hunter, Steven P. Treon
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3952–3959.
https://doi.org/10.1182/bloodadvances.2020001963
Published: 2020
Journal Articles

Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant

Clinical Trials & Observations
Scott R. Solomon, Melhem Solh, Xu Zhang, Stacey Brown, Katelin C. Jackson, H. Kent Holland, Lawrence E. Morris, Asad Bashey
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3669–3676.
https://doi.org/10.1182/bloodadvances.2020001958
Published: 2020
Includes: Supplemental data
Journal Articles

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors

Sondra Downey-Kopyscinski, Ellen W. Daily, Marc Gautier, Ananta Bhatt, Bogdan I. Florea, Constantine S. Mitsiades, Paul G. Richardson, Christoph Driessen, Herman S. Overkleeft, Alexei F. Kisselev
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2443–2451.
https://doi.org/10.1182/bloodadvances.2018016360
Published: 2018
Includes: Supplemental data